Get to know our clinical trials
Clinical trial of TTX-030 in combination with chemotherapy with or without budigalimab, compared to chemotherapy alone, to treat patients who have not received prior treatment for metastatic pancreatic adenocarcinoma
THIS STUDY IS CONDUCTED FOR THE FOLLOWING PURPOSE: TO OBSERVE WHETHER TTX-030 WITH OR WITHOUT BUDIGALIMAB IN COMBINATION WITH CHEMOTHERAPY HELPS PATIENTS WITH METASTATIC PANCREATIC CANCER. TO ANALYZE THE SAFETY OF TTX-030 WITH OR WITHOUT BUDIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC CANCER. TO OBSERVE WHETHER TTX-030 WITH OR WITHOUT TREATMENT COMBINED WITH BUDIGALIMAB HELPS A SPECIFIC SUBGROUP OF STUDY PARTICIPANTS.
Technical Summary
- PHASE 2, OPEN-LABEL, MULTICENTER, MULTICENTER, RANDOMIZED, 3-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TTX-030 IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT BUDIGALIMAB, COMPARED TO CHEMOTHERAPY ALONE, TO TREAT PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
- Code EudraCT: 2023-508356-19-00
- Protocol number: TTX-030-003
- Promoter: Trishula Therapeutics, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.